BioLineRx Ltd. (NASDAQ:BLRX) has been given a $3.00 price target by Oppenheimer Holdings, Inc. in a research report issued on Wednesday. The firm currently has a “buy” rating on the biotechnology company’s stock. Oppenheimer Holdings, Inc.’s price target indicates a potential upside of 164.32% from the stock’s previous close.
Several other research firms have also commented on BLRX. ValuEngine upgraded BioLineRx from a “sell” rating to a “hold” rating in a research report on Monday, July 17th. Roth Capital started coverage on BioLineRx in a research report on Thursday, August 3rd. They set a “buy” rating and a $3.00 price target for the company. Zacks Investment Research upgraded BioLineRx from a “sell” rating to a “hold” rating in a research report on Thursday, September 7th. Finally, Maxim Group set a $3.00 price target on BioLineRx and gave the stock a “buy” rating in a research report on Tuesday, August 8th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. BioLineRx currently has a consensus rating of “Buy” and a consensus target price of $2.88.
Shares of BioLineRx (BLRX) traded up 4.128% during midday trading on Wednesday, reaching $1.135. The company’s stock had a trading volume of 306,394 shares. BioLineRx has a one year low of $0.80 and a one year high of $1.38. The stock’s 50-day moving average is $1.12 and its 200-day moving average is $0.97. The company’s market capitalization is $108.53 million.
BioLineRx (NASDAQ:BLRX) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.05) EPS for the quarter, hitting the consensus estimate of ($0.05). On average, equities analysts expect that BioLineRx will post ($0.24) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.chaffeybreeze.com/2017/10/18/oppenheimer-holdings-inc-analysts-give-biolinerx-ltd-blrx-a-3-00-price-target.html.
A number of large investors have recently added to or reduced their stakes in BLRX. Citadel Advisors LLC boosted its holdings in BioLineRx by 443.4% in the first quarter. Citadel Advisors LLC now owns 105,986 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 86,481 shares during the period. Renaissance Technologies LLC purchased a new position in BioLineRx in the first quarter valued at $126,000. Finally, KCG Holdings Inc. boosted its holdings in BioLineRx by 715.9% in the first quarter. KCG Holdings Inc. now owns 175,156 shares of the biotechnology company’s stock valued at $168,000 after purchasing an additional 153,687 shares during the period. Hedge funds and other institutional investors own 32.27% of the company’s stock.
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.